182 related articles for article (PubMed ID: 16459332)
1. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
Croucher D; Saunders DN; Ranson M
J Biol Chem; 2006 Apr; 281(15):10206-13. PubMed ID: 16459332
[TBL] [Abstract][Full Text] [Related]
2. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
3. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
4. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
5. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
6. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
[TBL] [Abstract][Full Text] [Related]
7. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
[TBL] [Abstract][Full Text] [Related]
8. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
9. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.
Kounnas MZ; Henkin J; Argraves WS; Strickland DK
J Biol Chem; 1993 Oct; 268(29):21862-7. PubMed ID: 7691818
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
[TBL] [Abstract][Full Text] [Related]
11. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
Croucher DR; Saunders DN; Stillfried GE; Ranson M
Biochem J; 2007 Dec; 408(2):203-10. PubMed ID: 17696882
[TBL] [Abstract][Full Text] [Related]
12. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Bu G; Maksymovitch EA; Schwartz AL
J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Makarova AM; Lebedeva TV; Nassar T; Higazi AA; Xue J; Carinato ME; Bdeir K; Cines DB; Stepanova V
J Biol Chem; 2011 Jul; 286(26):23044-53. PubMed ID: 21540184
[TBL] [Abstract][Full Text] [Related]
14. High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.
Migliorini M; Li SH; Zhou A; Emal CD; Lawrence DA; Strickland DK
J Biol Chem; 2020 Jan; 295(1):212-222. PubMed ID: 31792055
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
Stefansson S; Lawrence DA; Argraves WS
J Biol Chem; 1996 Apr; 271(14):8215-20. PubMed ID: 8626514
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific expression of the relaxed conformation of plasminogen activator inhibitor-2 and low-density lipoprotein receptor-related protein in human term gestational tissues.
Tsatas D; Baker MS; Rice GE
J Histochem Cytochem; 1997 Dec; 45(12):1593-602. PubMed ID: 9389762
[TBL] [Abstract][Full Text] [Related]
18. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
[TBL] [Abstract][Full Text] [Related]
19. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
[TBL] [Abstract][Full Text] [Related]
20. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR.
Cortese K; Sahores M; Madsen CD; Tacchetti C; Blasi F
PLoS One; 2008; 3(11):e3730. PubMed ID: 19008962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
